Reinforcing readiness for BLA submission and market launch of its proprietary DNA-based lead product
SEOUL, South Korea, Aug. 20, 2018 /PRNewswire/ — ViroMed (084990:KS) announced its acquisition of a plasmid DNA production facility in San Diego, California from Vical Incorporated. With ViroMed’s first Phase III clinical trial of its lead product VM202 (donaperminogene seltoplasmid) for painful diabetic peripheral neuropathy (PDPN) nearing its completion, ViroMed, in joint venture partnership with a private equity investment firm, acquired the GMP ready facility that has been until recently a production site for clinical studies including phase IIIs in the US of DNA-based investigational new drugs.